Anthem Biosciences reported a temporary performance dip in Q1FY27 due to delayed client shipments. Despite this, analysts at Prabhudas Lilladher maintain a positive outlook, citing a strong product pipeline and upcoming commercialization of key specialty ingredients.
Detailed Coverage
Anthem Biosciences recently reported a softer performance for the first quarter of fiscal year 2027. According to the company, this result was primarily caused by the deferral of shipments to key clients. While this has impacted short-term numbers, the management indicated that these deliveries are now expected to be recognized in the subsequent quarters of the fiscal year.
Growth Strategy and Product Pipeline
The company’s future growth strategy relies heavily on its Contract Research and Development Manufacturing Organization (CRDMO) pipeline. Analysts expect that several late-stage projects will reach the commercialization stage within the next 18 to 24 months. A key area for investors to monitor is the Specialty Ingredients division, specifically the progress of the semaglutide API. The commercial success of this product remains dependent on receiving necessary approvals from the Central Drugs Standard Control Organisation (CDSCO).
Capital Spending and Financial Outlook
To support these long-term objectives, Anthem Biosciences has outlined plans for significant capital spending. The company intends to invest between INR 10 billion and 12 billion by the end of fiscal year 2028. A notable aspect of this expansion is the funding method; the management plans to finance these projects primarily through internal accruals rather than relying heavily on fresh debt. This approach is intended to preserve the balance sheet as the company scales its production capacity.
Financial projections from brokerage reports suggest a potential compound annual growth rate of approximately 21% for revenue and 22% for EBITDA through FY28. This expected growth is segmented across its three main business areas: CDMO services, Contract Research Organization (CRO) operations, and Specialty Ingredients. However, realizing these projections will depend on the successful and timely execution of the planned capacity expansion and the achievement of scheduled commercialization milestones.
Investor Monitorables
Investors may track several key developments in the coming quarters. First, the actual recovery in shipment volumes will confirm whether the Q1 performance was a genuine timing issue. Second, the progress of regulatory approvals for the semaglutide API will be a critical factor for the Specialty Ingredients division. Finally, monitoring the execution of the INR 10-12 billion capital spending program will be essential to ensure that the company maintains its financial health and avoids potential pressure on profit margins during the construction phase.